Drugs / tIRV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05596734 | Oct 2022 → Dec 2023 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-08-16 | BioNTech SE | Results Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age biontech.com ↗
In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-16 | BioNTech SE | Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tIRV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05596734 ↗ |
| Modality | Vaccine | “trivalent influenza vaccine (tIRV)” NCT05596734 ↗ |